Taiwan-based Bora Pharmaceuticals has acquired a sterile manufacturing facility from Emergent BioSolutions, according to a June 20 press release.
The 87,000-square-foot facility in Camden, Maryland, will have manufacturing services for sterile injectables and have four fill lines including lyophilization, vial filling and pre-filled syringe filling.
The $30 million agreement includes transferring assets, equipment and Emergent’s established workforce of approximately 350 employees.
The transaction is expected to close in Q3 and is subject to customary closing conditions, according to Emergent.
For Bora, the Camden facility acquisition represents part of its expansion strategy in the U.S.
“Bora has ambitious plans to enhance the newly acquired facility, and all staff currently based at the Camden site will be given the opportunity to remain in place and become part of the Bora team,” the company stated.
The acquisition also supports Bora's expansion into sterile drug product manufacturing and complements its biologics development and manufacturing services, according to the press release.
The Camden acquisition follows Bora Pharmaceutical's purchase of Minnesota-based Upsher-Smith Laboratories for $210 million earlier this year in an effort to build up its presence in North America.
Upsher-Smith Laboratories is a generics manufacturer with facilities in Plymouth and Maple Grove, Minnesota, that produced a range of drug dosage forms including oral solid, powders, liquid as well as packaging.
Bora Pharmaceuticals now has two U.S. facilities, five in Taiwan and one in Canada, according to its website.
Emergent's sale of its Camden facility follows its May announcement that it was shuttering its Baltimore and Rockville facilities as well and laying off 300 workers.
The Maryland-based pharmaceutical manufacturer is in the midst of restructuring operations with plans to save up to $80 million.
